GO
Loading...

Enter multiple symbols separated by commas

Abbott Laboratories

More

  • New Year Trends Monday, 12 Jan 2009 | 9:28 AM ET

    After starting off the year with a bang, the trend has been to the downside and is again this morning. The good news is that the credit market is continuing to improve, with lower Libor and a corporate bond market that is starting to look functional again.

  • Stock Strategist:  Two Conservative Stocks for 2009 Thursday, 11 Dec 2008 | 2:20 PM ET

    The new year is still three weeks away, but Keith Wirtz of Fifth Third Asset Management has a couple of stocks he thinks investors ought to own in 2009.  Both are stocks of conservative companies he likes because of their fundamentals, and are likely to do well as the market recovers. 

  • Three Stocks With 'Real Growth Potential' Wednesday, 10 Dec 2008 | 10:17 AM ET

    Eric Schoenstein of the Jensen Portfolio says equities remain the best bet in the long run. His advice: "You've got to start thinking more clearly about fundamentals of businesses, quality businesses that have real growth potential, cash flow generation opportunities."

  • After 50% Drop, Are Stocks Cheap? Monday, 24 Nov 2008 | 6:33 PM ET
    graphic_fast_money.jpg

    Investors are riddled with anxiety over one simple question. Are stocks cheap?

  • Stocks for a Down Market Tuesday, 11 Nov 2008 | 5:02 PM ET

    Even in a down market, there are stocks that buck the trend.

  • Lightning Round: Merck, Deere, Altria and More Friday, 31 Oct 2008 | 7:14 PM ET

    Cramer makes the call on viewers' favorite stocks.

  • Mad Mail: Is J&J a Buy? Thursday, 30 Oct 2008 | 8:27 PM ET

    Plus, Cramer offers young investors advice on which stocks they should consider buying and more.

  • Lightning Round: Nike, State Street, Mosaic and More Thursday, 30 Oct 2008 | 8:13 PM ET

    Cramer makes the call on viewers' favorite stocks.

  • Analysts Target Healthy Drug Stocks Tuesday, 21 Oct 2008 | 1:05 PM ET

    Pharmaceutical stocks were winners today on the earnings front, and CNBC guests say they can be winners on the portfolio front as well.

  • Web Extra: Antidote For Market Volatility Friday, 17 Oct 2008 | 7:18 PM ET
    webxtra_thumb.jpg

    Despite a slowing economy, drug stocks such as Abbott Labs and Genentech posted positive earnings reports. Is health care the best defensive play in this market?

  • Time To Get Back In? Thursday, 16 Oct 2008 | 6:37 PM ET
    graphic_fast_money.jpg

    After the volatile trading of the past several days, professional and amateur investors alike are throwing in the towel. But that might be a mistake.

  • Your First Move For Thursday October 16th Wednesday, 15 Oct 2008 | 7:08 PM ET
    graphic_final_trade.jpg

    Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!

  • Heart Drugs Could Save Billions Over Stents: Study Wednesday, 24 Sep 2008 | 4:14 PM ET

    A first-of-its-kind study shows that putting hundreds of thousands of American heart patients on drugs instead of giving them a stent could save the country billions of dollars a year.

  • Abbott & Boston Scientific: Rising Stent Stars Wednesday, 17 Sep 2008 | 12:21 PM ET
    Boston Scientific Corp.

    Not too long ago, some had written off the potential for significant growth to resume in sales of the little wire mesh tubes that are painted with special drugs to help keep arteries from reclogging.

  • Cramer makes the call on viewers' favorite stocks.

  • Abbott's Covering The Bases Thursday, 14 Aug 2008 | 1:28 PM ET

    The market cap of Dow component Johnson & Johnson is a whopping $200 billion. Abbott Labs is valued at less than half that. But think of ABT as kind of a mini-me JNJ because like Johnson & Johnson, ABT has cobbled together a similar three-siloed business of drugs, devices and consumer products.

  • Stents, Drugs or Both: Debate May Get New Life Wednesday, 13 Aug 2008 | 6:08 PM ET

    A new study and an editorial in a major medical journal could reignite the debate over whether drugs or stents or a combination of both are better for the millions of Americans with heart trouble.

  • Week Ahead: Volatile Stocks, Oil Watch, Fed on Hold Monday, 4 Aug 2008 | 11:12 AM ET
    FED_RESERVE3.jpg

    Oil prices will be the trigger for stocks in the week ahead. The Fed meets Tuesday and as usual, traders will watch for nuances in the Fed's post-meeting statement.

  • The State of Statins & Stents Friday, 25 Jul 2008 | 11:14 AM ET
    Heart Stent

    Leerink Swann, which specializes in healthcare equities research, is out with a couple of noteworthy surveys--one on the collateral damage to Merck and Schering-Plough's Vytorin this week and the other on drug-coated stents from Abbott Labs, Boston Scientific, Johnson & Johnson and Medtronic.

  • Web Extra: Here Comes The Sun Wednesday, 16 Jul 2008 | 6:54 PM ET
    webxtra_thumb.jpg

    In Wednesday’s Web Extra Pete Najarian reveals why he thinks the solar trade is starting to turn. Also “if you want to get into drugs” Guy Adami has your play.